https://charts.traderzeitung.de/phases/CA74319B5027
string(1416) "{"isin":"CA74319B5027","name":"Profound Medical Corp","stock_id_xnas":10391071,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.09,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":6.22,"close_at":"2026-09-21 22:25:00","complete":true,"perf_pct":2.1346}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.87,"close_at":"2026-09-22 21:57:00","complete":true,"perf_pct":-5.627},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.74,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-2.2147},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"
Profound Medical
Trading-Room

Profound Medical Aktie News & Nachrichten

[WKN: A2PTXJ | Symbol: PROF]
Realtimekurs
   
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Profound Medical gefunden werden.

Profound Medical Nachrichtenticker öffnen
MT Newswires 01.09.2026 14:39 Uhr

Profound Medical ernennt Richard Fabian zum Präsidenten

08:38 AM EDT, 01.09.2026 (MT Newswires) -- Profound Medical (PROF) teilte am Dienstag mit, dass das Unternehmen Richard Fabian mit sofortiger Wirkung

MT Newswires 14.08.2026 22:50 Uhr

Profound Medical ernennt Matthew Sobczyk zum Interims-CFO

04:49 PM EDT, 14.08.2026 (MT Newswires) -- Profound Medical (PROF) teilte am Freitag mit, dass Matthew Sobczyk mit sofortiger Wirkung zum Interims-Fin

MT Newswires 24.07.2026 21:36 Uhr

Branchen-Update: Gesundheitsaktien am späten Nachmittag im Plus

03:35 PM EDT, 24.07.2026 (MT Newswires) -- Gesundheitsaktien stiegen am späten Freitagnachmittag; der NYSE Healthcare Index legte um 0,6 % zu und der

MT Newswires 24.07.2026 21:12 Uhr

Sektor-Update: Gesundheitswesen

03:11 PM EDT, 24.07.2026 (MT Newswires) -- Aktien aus dem Gesundheitswesen legten am Freitagnachmittag zu, wobei der NYSE Healthcare Index um 0,6 % st

MT Newswires 24.07.2026 19:19 Uhr

Profound Medical meldet neue statistisch signifikante TULSA-Studienergebnisse; Aktien steigen

13:18 Uhr EDT, 24.07.2026 (MT Newswires) -- Profound Medical (PROF) gab bekannt, dass neue Daten aus einer Level-1-Evidenzstudie des MRT-geführten TUL